Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 5/20 | 0.33 |
| ▸ | PRKCA | P17252 | 2/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.31 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918550 | 0.90 | PRKCA (0.30) | PRKCAPRKCQMAP3K11 | |
| SCHEMBL9921780 | 0.80 | ALDH1A1 (0.47) | ALDH1A1SMN1; SMN2HPGDJAK1JAK3 | |
| SCHEMBL9918548 | 0.79 | JAK2 (0.36) | ALDH1A1SMN1; SMN2NPC1PRKCAPRKCQ | |
| SCHEMBL9918554 | 0.73 | PDE3B (0.40) | PDE3BPDE3APRKCAPRKCQMAP3K11 | |
| SCHEMBL9918552 | 0.72 | HTT (0.39) | ALDH1A1POLBHPGDNPC1JAK1 | |
| SCHEMBL9921664 | 0.71 | MAP3K11 (0.41) | KDM4EALDH1A1HPGDMAP3K11JAK1 | |
| SCHEMBL9918533 | 0.70 | MAP3K11 (0.41) | KDM4EALDH1A1SMN1; SMN2POLBHPGD | |
| SCHEMBL9918551 | 0.69 | MAP3K11 (0.35) | PRKCAPRKCQMAP3K11JAK1JAK3 | |
| SCHEMBL9921982 | 0.67 | KDM4E (0.44) | KDM4EALDH1A1SMN1; SMN2PDE3BPDE3A | |
| SCHEMBL9921770 | 0.67 | SMN1; SMN2 (0.42) | ALDH1A1SMN1; SMN2PDE3BPDE3APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| WO-2011031554-A2 | HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | KDM4E 477/4885ALDH1A1 1507/4885SMN1; SMN2 4199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.